Diabetes mellitus associated with immune checkpoint inhibitors treatment: A clinical case by atezolizumab

Endocrinol Diabetes Nutr (Engl Ed). 2021 May;68(5):363-365. doi: 10.1016/j.endien.2021.08.007. Epub 2021 Sep 9.

Authors

Pablo Rodríguez de Vera Gómez¹, María Del Castillo Tous Romero², Cristóbal Morales Portillo², Isabel Serrano Olmedo², María Asunción Martínez Brocca²

Affiliations

¹ Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Universitario Virgen Macarena, Sevilla, Spain. Electronic address: pablordevera@gmail.com.
² Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Universitario Virgen Macarena, Sevilla, Spain.

PMID: 34556267
DOI: 10.1016/j.endien.2021.08.007

No abstract available

Publication types

Case Reports

MeSH terms

Antibodies, Monoclonal, Humanized* / adverse effects
Diabetes Mellitus* / chemically induced
Humans
Immune Checkpoint Inhibitors / adverse effects*

Substances

Antibodies, Monoclonal, Humanized
Immune Checkpoint Inhibitors
atezolizumab